Liliumtx
1 known investors
Lilium develops genetic medicines that selectively target pathogenic T cells in autoimmune diseases using engineered delivery vehicles for precision immune reprogramming. The company focuses on treating T-cell mediated autoimmune diseases and oncology indications that currently lack effective treatments.
Investors · 1
Competitors · 7
by search overlapLuminary Therapeutics5 shared keywords
Lyell5 shared keywordsLyell is a clinical-stage biotech developing next-generation CAR T-cell product candidates intended as one-time treatments for patients with cancer, targeting both hematologic malignancies and solid tumors. The company owns and operates its own manufacturing facility to control its cell therapy supply chain.
Lirum Therapeutics4 shared keywordsLirum Therapeutics is a biopharmaceutical company that acquires, develops, and commercializes novel drug candidates for the treatment of difficult-to-treat, debilitating diseases. It was created by the former management team of Stemline Therapeutics.
Telo Therapeutics, Inc.3 shared keywordsTelo Therapeutics is a biotechnology company developing orally bioavailable next-generation small-molecule inhibitors of nuclear transport as cancer treatments. Its lead program targets multiple myeloma and other cancers, and the company is raising a Series A to advance toward IND and a Phase 1 trial.
Calliotx3 shared keywordsCallio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.
Valink Therapeutics3 shared keywordsValink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.
Solu3 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Liliumtx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Liliumtx do?
- Lilium develops genetic medicines that selectively target pathogenic T cells in autoimmune diseases using engineered delivery vehicles for precision immune reprogramming. The company focuses on treating T-cell mediated autoimmune diseases and oncology indications that currently lack effective treatments.
- Who are Liliumtx's investors?
- Liliumtx's investors include Ulu Ventures.